Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

My previous session
Most popular
Analysis summaryMarketScreener Strategies

Patrick Rejaunier

Equity Analyst
share with twitter share with LinkedIn share with facebook
share via e-mail

Good timing to anticipate the return of volatility

Strategy published on 11/17/2016 | 15:39
long trade
Stop-loss triggered
Entry price : 91.67€ | Target : 98.82€ | Stop-loss : 87.92€ | Potential : 7.8%
After several weeks of range-bound movement, shares in Bayer AG could enter into a new clear trend. The exit out of the current trading range could be the signal for a return of volatility.
Investors have an opportunity to buy the stock and target the € 98.82.
  • The company has solid fundamentals for a short-term investment strategy.

  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • Below the resistance at 99.3 EUR, the stock shows a negative configuration when looking looking at the weekly chart.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2018 39 117 M
EBIT 2018 7 261 M
Net income 2018 4 895 M
Debt 2018 39 658 M
Yield 2018 3,74%
P/E ratio 2018 14,96
P/E ratio 2019 13,99
EV / Sales 2018 2,82x
EV / Sales 2019 2,26x
Capitalization 70 706 M
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Bayer Technical Analysis Chart | MarketScreener
Duration : Period : Week
Bayer Technical Analysis Chart | MarketScreener